INTRODUCTION {#sec4}
============

Exposure to radiation produces lesions to the biological system and causes a series of physiological symptoms, which results in many complications. Since the small intestine is one of the organs in which cells proliferate rapidly, it is highly radiosensitive, with the result that radiation injury tends to appear soonest after exposure. Irradiation leads to the well-known symptoms of gastrointestinal (GI) radiation syndrome, for instance, GI hemorrhage, endotoxemia, bacterial infection, anorexia, nausea, vomiting, diarrhea and loss of electrolytes and fluid \[[@ref1]\]. People who receive radiotherapy develop gastrointestinal syndrome including radiation enteritis easily and their quality of life is reduced \[[@ref2]\]. To date, there is no clinical effective treatment for radiation enteritis. Current research into radiation enteritis mainly focuses on reducing the risk of the syndrome, and the widely used radiation protectant is amifostine \[[@ref3]\]. Amifostine is a cytoprotective agent approved for protection during radiotherapy. It may cause adverse effects, such as hypotension, vomiting and allergic reactions \[[@ref6]\]. As a result, amifostine is unattractive in preventing radiation-induced intestinal injury. With the wide range use of radiotherapy in cancer treatment, there is an urgent need to develop highly effective radioprotective agents with fewer adverse effects for radiation enteritis.

Ginger, is the rhizome of zingiber officinale roscoe. It has a long history in traditional medicine for the treatment of various diseases. Recent studies have shown that ginger and its extract possess a radioprotective effect \[[@ref7], [@ref8]\]. Zingerone is an essential oil extracted from ginger that has various biological functions, including antioxidant, anti-inflammatory and antiapoptosis properties \[[@ref9]\]. Zingerone is known as a potent free-radical scavenger with protective properties against reactive oxygen species (ROS)-mediated DNA damage by scavenging and degrading free radicals and ROS \[[@ref13], [@ref14]\]. Zingerone was also found to attenuate cellular senescence and dampens production of pro-inflammatory cytokines induced by UVB irradiation \[[@ref15]\]. However, zingerone is insoluble in water and ethanol was used as cosolvent when administered orally \[[@ref16]\]. Cysteamine has been known as a radioprotector for decades. In patients treated with ionizing radiations, the symptoms of radiation sickness are often eliminated when cysteamine is adminstered intravenously in a 200 mg dose \[[@ref17]\]. Brown hypothesized that cysteamine may limit the propagation of DNA damage and increase the fidelity of DNA repair to inhibit proliferaton and thereby protect the cells \[[@ref18]\]. However, this exogenous thiol compound can generate an oxidant stress, which makes cysteamine cytotoxic \[[@ref19]\]. Moreover, a near-toxic dose is needed to achieve adequate protection \[[@ref20]\].

In this study, for the first time, we developed a new radioprotector by incorporating zingerone and cysteamine together so as to achieve a higher radioprotective effect and optimize their fundamental physicochemical properties. The newly synthesized compound was converted into its hydrochloride (thiazolidine hydrochloride, TZC01) to obtain higher water solubility. The protective effects of TZC01 on ionzing radiation-induced intestinal damage in mouse models exposed to 12 Gy abdominal irradiation (ABI) was evaluated. Our data showed that TZC01 could improve the survival rate of mice and reduce the radiation-induced intestinal damage.

MATERIALS AND METHODS {#sec5}
=====================

Animals and ethics approval and consent to participate {#sec6}
------------------------------------------------------

Male C57BL/6J mice (8-10 weeks) were purchased from Beijing HFK Bioscience Co., Ltd. (Beijing, China). Animals were bred in the certified animal facility in the Institute of Radiation Medicine (IRM) of the Chinese Academy of Medical Sciences (CAMS).

All experimental procedures were carried out in accordance with the NIH Guidelines for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of IRM-CAMS (Permit Number 20180310). The animals were cared for in accordance with the dictates of the National Animal Welfare Law of China.

Synthesis of TZC01 {#sec7}
------------------

To a suspension of cysteamine hydrochloride (3.25 g, 28.6 mmol) and triethylamine (2.9 g, 28.6 mmol) in toluene was added zingerone (5 g, 25.7 mmol) and *p*-toluenesulfonic acid monohydrate (0.245 g, 1.3 mmol) while stirring. The reaction mixture was refluxed for 6 h with a Dean-Stark water trap. The reaction mixture was cooled, washed with 0.1 M sodium hydroxide solution and the aqueous phase was extracted with ethyl acetate (50 mL × 2). The combined toluene and ethyl acetate phase was washed with brine and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure to give the crude product which was purified by column chromatography elution with hexane and ethyl acetate to obtain the thiazolidine (4.47 g, 68.5%). Thiazolidine was reacted with a solution of hydrogen chloride in methanol to afford thiazolidine hydrochloride (5.11 g, 100%). MS (ESI): m/z calcd for C13H19NO2S \[M+H\]^+^: 254.1, found: 254.2. 1H NMR (400 MHz, DMSO) δ 10.32 (br s, 2H), 8.76 (br s, 1H), 6.84 (d, *J* = 2 Hz, 1H), 6.70 (d, *J* = 8.0 Hz, 1H), 6.63 (dd, *J* = 8.0 Hz, 2 Hz, 1H), 3.76 (s, 3H), 3.72-3.58 (m, 2H), 3.33-3.21 (m, 2H), 2.72-2.58 (m, 1H), 2.63-2.53 (m, 1H), 2.33-2.13 (m, 2H), 1.74 (s, 3H). 13C NMR (100 MHz, DMSO) δ 147.9, 145.2, 131.7, 120.8, 115.8, 113.0, 75.3, 56.0, 46.9, 42.6, 40.5, 40.3, 40.1, 39.9, 39.7, 39.5, 39.3, 31.3, 29.3, 25.9.

Irradiation and treatment {#sec8}
-------------------------

Irradiation was performed using a X source housed in an Exposure Instrument Biological X-ray radiometer (Rad Source, Buford, Georgia, USA) at a dose-rate of 1.2 Gy per min. We first carried out two mouse survival rate experiments. Mice were randomly divided into five groups (*n*=10), including Control, Solvent, TZC01 (50 mg/kg), TZC01 (100 mg/kg) and TZC01 (200 mg/kg). All four groups except the control group were exposed to 12 Gy ABI. The Control group were treated similarly to the irradiation group but without exposure to IR. Mice were randomly divided into five groups (*n*=10), including Control, Solvent, TZC01 (100 mg/kg), cysteamine (100 mg/kg) and zingerone (100 mg/kg). All four groups except the Control group were exposed to 12 Gy ABI. Control group were treated similarly to the irradiation group but without exposure to IR.

In the remaining experiments, the mice were randomly divided into three groups (*n*=5): (a) Control; (b) Solvent; (c) TZC01. Groups Solvent and TZC01 received 12 Gy ABI. The TZC01 group was intragastrically administered with a dose of 100 mg/kg 1 hour before the irradiation, and was continuously administered for 2 days after irradiation. Mice of groups Control and Solvent were treated with solvent similarly to the procedure described for the treatment group.

Histological analysis {#sec9}
---------------------

Three days after ABI, mice were sacrificed and paraffin sections were prepared from small intestine tissue and then stained with hematoxylin--eosin (H&E) and analyzed under a microscope. The number of intestinal crypts were counted using ImageJ 1.37 software to assess the effect of TZC01 on the apoptosis of irradiated mice intestinal crypt cells.

Immunohistochemistry analysis {#sec10}
-----------------------------

Mice were sacrificed after 3 days of ABI and small intestine tissues were fixed in 10% neutral formalin. The duodenum, jejunum and ileum of appropriate size were selected and embedded in wax. They were cut into 4 μm wax pieces and attached to the glass slide and dried in a dryer. After antigen retrieval, nonspecific sites were blocked with goat serum for 15 min at room temperature. Sections were incubated with primary antibody overnight at 4°C, including antibodies against Lgr5 (Abcam, Cambridge, MA, USA), villi (Abcam), lysozyme (Abcam) and Ki67 (Novus, Littleton,CO, USA). After thoroughly washing with PBS, the secondary antibody was added and incubated at room temperature for 1 h at 37°C, and positive cells were detected by a DAB (3, 3'-Diaminobenzidine tetrahydrochloride hydrate) kit (Sigma-Aldrich).

Immunofluorescence analysis {#sec11}
---------------------------

The steps before antigen retrieval are the same as described for immunohistochemistry. The tissues were washed thoroughly with PBS and goat serum was added for 1 h at room temperature. Sections were incubated with primary antibody overnight at 4°C, including antibodies against γH2AX (BD biosciences, NJ, USA) and caspase-3 (CST, MA, USA). After thorough washing with PBS, the slices were incubated with a secondary antibody mixed with DAPI (4', 6-diamidino-2-phenylindole) in a 37°C incubator for 40 min in the dark. The slices were sealed and observed under a laser scanning confocal microscope.

Statistical analysis {#sec12}
--------------------

All analyses were performed using GraphPad Prism6 software, and differences were considered significant at *P* \< 0.05. Log-rank test was used to analyze the significant difference of survival rate among groups and Tukey's test was used to analyze other data.

RESULTS {#sec13}
=======

Synthesis and characterization of TZC01 {#sec14}
---------------------------------------

In this study, we designed and synthesized a novel compound, TZC01, to contain properties of zingerone and cysteamine. As shown in [Fig. 1](#f1){ref-type="fig"}, zingerone reacted with cysteamine in toluene under reflux to give thiazolidine. Then, thiazolidine was treated with a solution of HCl in MeOH to produce TZC01. The total yield of TZC01 was 68.5%. The structure of the synthesized compound was characterized by nuclear magnetic resonance (NMR) and electrospray ionization mass spectrometer (ESI-MS) (see Supplementary [Fig. S1](#sup1){ref-type="supplementary-material"}, [Fig. S2](#sup1){ref-type="supplementary-material"} and [Fig. S3](#sup1){ref-type="supplementary-material"}, available as Supplementary material online). The results showed that the new compound was successfully prepared with a facile synthetic approach.

![Synthesis of TZC01. i, triethylamine, p-toluenesulfonic acid monohydrate, toluene, reflux; ii, HCl/MeOH, 0°C.](rrz065f1){#f1}

TZC01 improves the survival rate of mice after ABI {#sec15}
--------------------------------------------------

To determine the protective effect of TZC01 on mice exposed to radiation, we first observed the survival rate of mice after 12 Gy ABI ([Fig. 2](#f2){ref-type="fig"}). The mice were treated with TZC01 in three dosages (50 mg/kg, 100 mg/kg, 200 mg/kg). We found that the best effect was obtained when the dose of TZC01 was 100 mg/kg. The solvent-administered group began to die on the fourth day after 12 Gy ABI. The mortality rate was 80%, and the average survival time was 4 days. The average survival times of the of zingerone-administration or cysteamine-administration groups were 4.5 days. For the TZC01-administration group, the average survival time was 5.5 days. This result suggested that TZC01 had not only a certain protective effect on radiation-induced intestinal damage, but also presented an improved protective effect compared with zingerone or cysteamine. It is worth noting that TZC01-administrated mice die soon after X-irradiation because the irradiation dose and dose-rate were too high to be tolerated by mice.

![Survival curves after 12 Gy of abdominal irradiation. (**a**) The effect of different doses of TZC01 on survival rate in mice (*P* \< 0.05, *n* = 10 per group). (**b**) The effect of the same dose of TZC01, zingerone and cysteamine on survival rate in mice (*P* \< 0.05, *n* = 10 per group). *P* values were calculated by the log-rank test.](rrz065f2){#f2}

TZC01 protects against radiation-induced gastrointestinal injury {#sec16}
----------------------------------------------------------------

In order to test whether TZC01 has a radiation protection effect, we evaluated the morphological changes in the small intestine of mice. The villus length and crypt density of the small intestine were significantly reduced in the Solvent group compared with the TZC01 group at 3 days after 12 Gy ABI ([Fig. 3a and c](#f3){ref-type="fig"}). It is gratifying that the mice treated with TZC01 have significantly improved intestinal villus length and crypt biology. Compared with the Solvent group, the number of crypts in the TZC01 group was increased by 41.7% (*P* \< 0.05), and the villus length of the small intestine increased by 16.39% on average (*P* \< 0.01) ([Fig. 3b and d](#f3){ref-type="fig"}). The results show that TZC01 has a protective effect on the damage to intestinal morphology.

![(**a**) H&E-stained small intestine cross-sectional structure. (**b**) Histogram showing the number of crypts. (**c**) Immunohistochemistry images showing the expression of Villi. (**d**) Histogram demonstrating villus length in intestinal section from the Control group, Solvent-treated group and TZC01-treated group. The results are represented as mean ± SD, *n* = 5 mice per group. ^\*^*P*\<0.05, ^\*\*^*P*\<0.01, using Tukey's test.](rrz065f3){#f3}

Lgr5 is a well-established adult intestinal stem cell marker \[[@ref21]\]. The regenerating rate of the intestinal lining is due to the population of stem cells at the base of the intestinal crypt. Thus, Lgr5 levels represent radiation-induced intestinal regeneration. Three days after administration of 12 Gy ABI to mice, the number of Lgr5^+^ intestinal stem cells in mice treated with TZC01 was significantly higher than that in mice treated with solvent ([Fig. 4a and b](#f4){ref-type="fig"}). Ki67 is a nuclear antigen present in proliferating cells and is one of the most widely used proliferating cell markers \[[@ref22]\]. Therefore, ki67 levels also represent radiation-induced intestinal proliferation. The results show the number of Ki67-positive cells in the TZC01 group was significantly higher than that of solvent group after ABI ([Fig. 4c and d](#f4){ref-type="fig"}). Lysozyme is a protein secreted by Paneth cells \[[@ref23]\]. Paneth cells residing at the base of the small intestinal crypts contribute to the mucosal intestinal first-line defense by secreting granules filled with antimicrobial polypeptides including lysozyme \[[@ref24]\]. We found a significant improvement in the number of lysozyme^−^ positive cells in the TZC01 group compared with the solvent group ([Fig. 4e and f](#f4){ref-type="fig"}). These data show that TZC01 can effectively improve the proliferation and differentiation of small-intestine crypt cells.

![Radiation protection of TZC01. The small intestinal sections were analyzed by immunohistochemistry. (**a**) Photomicrograph of Lgr5 immunostaining section of Control, Solvent and TZC01 groups. (**b**) Histogram showing Lgr5-positive cells quantified in five crypts per section. (**c**) Immunostaining images showing quantitative analysis of Ki67 expression of intestinal crypts. (**d**) Histogram demonstrating Ki67-positive cells counted in five crypts per section. (**e**) Representative immunohistochemistry images for lysozyme-stained sections of small intestine. (**f**) Histogram showing the number of paneth cells per five crypts. The results are represented as mean ± SD, *n* = 5 mice per group. ^\*\*^*P*\<0.01. ^\*\*\*^*P*\<0.005, using Tukey's test.](rrz065f4){#f4}

Phosphorylation of H2AX to form γH2AX is a hallmark of DNA double-strand breaks \[[@ref25]\]. As shown in [Fig. 5](#f5){ref-type="fig"}, the expression of γ-H2AX in the small intestine of the Solvent group was increased 88.8% compared with the Control group. Compared with the Solvent group, the expression level of γH2AX protein in crypt of the TZC01 group was decreased by 77.6%, and the difference was significant (*P*\<0.005). The results indicate that TZC01 can reduce radiation-induced DNA damage. This data showed that TZC01 could attenuate DNA damage of the small intestine after 12 Gy ABI.

![TZC01 attenuates DNA damage of mice after ABI. The small intestines of control mice, solvent-treated mice and TZC01-treated mice were obtained at 3 days after 12 Gy ABI. (**a**) Representative immunofluorescence images for the expression of γH2AX in the small intestine (red, γH2AX; blue, DAPI). (**b**) Histogram demonstrating quantitative analysis of γH2AX-positive cells per view field. The results are represented as mean ± SD, *n* = 5 mice per group. ^\*\*\*^*P*\<0.005, using Tukey's test.](rrz065f5){#f5}

Caspase-3 is the most important terminal cleavage enzyme in the process of apoptosis \[[@ref26]\]. Thus, we assessed the caspase-3 levels of intestinal tissues by DAPI and caspase-8 staining ([Fig. 6a and b](#f6){ref-type="fig"}). The expression level of caspase-3 can reflect the apoptosis of cells. Compared with the Solvent group, the expression level of caspase-3 in the TZC01 administration group was reduced by 75.5% (*P*\<0.005). These data demonstrate that TZC01 treatment can reduce apoptosis and protect against intestinal damage caused by radiation.

![TZC01 reduces apoptosis in the small intestine after ABI. (**a**) Representative DAPI and caspase-3 staining images of the small intestine (red, caspase3; blue, DAPI). (**b**) Histogram showing quantitative analysis of caspase3-positive cells per field of view. The results are represented as mean ± SD, *n* = 5 mice per group. ^\*\*\*^*P*\<0.005, using Tukey's test.](rrz065f6){#f6}

DISCUSSION {#sec17}
==========

Abdominal local radiotherapy is a common treatment for abdominal and pelvic tumors. Although a precise radiation can be applied to tumor sites, other surrounding normal tissues, especially intestine, may be affected and damaged. In addition, the irradiation of individuals in a nuclear accident and patients with localized radiotherapy, for conditions such as leukemia, can cause damages to the digestive tract, especially the intestines. Radiation-induced intestinal damage is an important cause of acute gastrointestinal symptoms and death in patients. Ionizing radiation can cause abnormal changes in intestinal crypt, resulting in inhibition of epithelial cell proliferation, increasing intestinal stem cell apoptosis, blocking the regeneration of villus epithelium, destroying the integrity of villus epithelial structure, inducing intestinal barrier dysfunction, and even causing bacteremia. In severe cases, the individual will die \[[@ref23]\]. To date, there is no effective clinical radioprotector to prevent intestinal injury to combine with radiotherapy for cancer patients. It is crucial to develop protective agents against radiation damage of gastrointestinal cells \[[@ref27]\]. In the present study, TZC01 enhanced the survival rates of mice after exposure to 12 Gy ABI, indicating that TZC01 protects against radiation-induced intestinal injury.

Lgr5 is an intestinal stem cell marker, we visualized stem cells and studied their behavior and differentiation in this case. We found that after 12 Gy of ABI, the number of Lgr5-positive stem cells in the TZC01 administration group was significantly higher than that in the Solvent group. As shown in [Fig. 4](#f4){ref-type="fig"}, other differentiated cells such as Paneth cells were increased after ABI, indicating that TZC01 can protect against intestinal injury caused by radiation in the small intestine by promoting the proliferation and differentiation of intestinal stem cells. The increased expression of Ki67, a proliferative marker in the small intestine, in the TZC01-treated group may indicate the recovery of intestinal damage after IR. The epithelium of the small intestine contains crypts and villi. Intestinal stem cells are located at the bottom of the crypt and are responsible for maintaining intestinal epithelial homeostasis and regeneration after injury \[[@ref28], [@ref29]\]. Our results show that the structural integrity of the small intestine villi is improved after irradiation with 12 Gy in TZC01-treated mice. These results indicate that TZC01 may have protective effects on intestinal damage caused by radiation.

The main cytotoxic effects of ionizing radiation are related to various DNA damages including double-strand breaks. Double-strand breaks can lead to chromosomal aberrations, which can lead to lesions such as most biological damage including cell death \[[@ref30]\]. In this study, we found that the expression level of γH2AX was lower in the TZC01 group than in the solvent group. Caspase-3 is an apoptotic executor, which was used as an indicator of intestinal cell apoptosis in our study \[[@ref31], [@ref32]\]. Caspase-3 gene expression in γ-radiation-induced cardiac apoptosis was significantly downregulated by zingerone in previous reports \[[@ref33]\]. In this study, apoptosis was reduced in the TZC01 group compared with the Solvent group. The expression of caspase-3 in the small intestines of the TZC01 group was also decreased compared with the Solvent group. These results indicate that TZC01 has an inhibitory effect on radiation-induced apoptosis of small intestinal cells.

Both zingerone and cysteamine have been widely studied as radioprotectors. Zingerone has anti-oxidant, anti-inflammatory and anti-apoptosis properties. The poor water solubility of zingerone is the main problem for its development as a new radioprotective agent. Cysteamine may increase the fidelity of DNA repair to protect the cells. However, cysteamine causes oxidant stress, leading to cytotoxity. For the first time, we synthesized a new radioprotector by incorporating both zingerone and cysteamine. We hoped to combine the two different radioprotectors in TZC01 to produce a compound with improved physicochemical properties. Our research indicates that TZC01 may play a protective role in radiation-induced intestinal damage by promoting proliferation and differentiation of intestinal crypt stem cells, inhibiting apoptosis and reducing DNA damage. This study provides a strong basis for the development of a novel radioprotective agent by incorporating multiple radioprotectors.
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